300 related articles for article (PubMed ID: 21502969)
21. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial.
Bjerklund Johansen TE; Baker TM; Black LK
BJU Int; 2012 Mar; 109(5):731-8. PubMed ID: 21933326
[TBL] [Abstract][Full Text] [Related]
23. Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression.
D'Agate S; Chavan C; Manyak M; Palacios-Moreno JM; Oelke M; Michel MC; Roehrborn CG; Della Pasqua O
World J Urol; 2021 Jul; 39(7):2635-2643. PubMed ID: 33337513
[TBL] [Abstract][Full Text] [Related]
24. Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.
Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Palacios JM; Vasylyev A; Manyak MJ
World J Urol; 2017 Mar; 35(3):421-427. PubMed ID: 27334136
[TBL] [Abstract][Full Text] [Related]
25. Dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic enlargement.
Ismail M; Hashim H
Drugs Today (Barc); 2012 Jan; 48(1):17-24. PubMed ID: 22384457
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C;
Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
[TBL] [Abstract][Full Text] [Related]
27. Understanding Treatment Response in Individual Profiles of Men with Prostatic Enlargement at Risk of Progression.
Gravas S; Palacios-Moreno JM; Thompson D; Concas F; Kamola PJ; Roehrborn CG; Oelke M; Kattan MW; Averbeck MA; Manyak M; Cortés V; Lulic Z
Eur Urol Focus; 2023 Jan; 9(1):178-187. PubMed ID: 35985933
[TBL] [Abstract][Full Text] [Related]
28. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
Oelke M; Giuliano F; Mirone V; Xu L; Cox D; Viktrup L
Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
[TBL] [Abstract][Full Text] [Related]
29. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS
BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
[TBL] [Abstract][Full Text] [Related]
30. Dutasteride: a review of its use in the management of prostate disorders.
Keam SJ; Scott LJ
Drugs; 2008; 68(4):463-85. PubMed ID: 18318566
[TBL] [Abstract][Full Text] [Related]
31. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
Roehrborn CG
BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
[TBL] [Abstract][Full Text] [Related]
32. Nocturia improvement in the combination of Avodart(®) and tamsulosin (CombAT) study.
Oelke M; Roehrborn CG; D'Ancona C; Wilson TH; Castro R; Manyak M
World J Urol; 2014 Oct; 32(5):1133-40. PubMed ID: 24804842
[TBL] [Abstract][Full Text] [Related]
33. Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia.
Hong SK; Min GE; Ha SB; Doo SH; Kang MY; Park HJ; Yoon CY; Jeong SJ; Byun SS; Lee SE
BJU Int; 2010 Apr; 105(7):970-4. PubMed ID: 19793378
[TBL] [Abstract][Full Text] [Related]
34. Model-based meta-analysis of the time to first acute urinary retention or benign prostatic hyperplasia-related surgery in patients with moderate or severe symptoms.
D'Agate S; Chavan C; Manyak M; Palacios-Moreno JM; Oelke M; Michel MC; Roehrborn CG; Della Pasqua O
Br J Clin Pharmacol; 2021 Jul; 87(7):2777-2789. PubMed ID: 33247951
[TBL] [Abstract][Full Text] [Related]
35. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia.
Zhou Z; Cui Y; Wu J; Ding R; Cai T; Gao Z
BMC Urol; 2019 Mar; 19(1):17. PubMed ID: 30871552
[TBL] [Abstract][Full Text] [Related]
36. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH.
Chung BH; Roehrborn CG; Siami P; Major-Walker K; Morrill BB; Wilson TH; Montorsi F
Prostate Cancer Prostatic Dis; 2009; 12(2):152-9. PubMed ID: 18813219
[TBL] [Abstract][Full Text] [Related]
38. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
Issa MM; Runken MC; Grogg AL; Shah MB
Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
[TBL] [Abstract][Full Text] [Related]
39. [Combined dutasteride and tamsulosin].
Sciarra A
Urologia; 2011; 78(4):317-9. PubMed ID: 22101551
[No Abstract] [Full Text] [Related]
40. [Combination drug therapy in patients with BPH].
Kuzmenko AV; Kuzmenko VV; Gyaurgiev TA
Urologiia; 2018 Mar; (1):101-105. PubMed ID: 29634142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
